Systemic interferon gamma treatment in severe atopic dermatitis

Reinhold, Uwe; Kukel, Sylvia; Brzoska, Josef; Kreysel, H. W.

doi:10.1016/0190-9622(93)70152-j

Cited by 91 publications

(52 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 Interferon gamma has consistently demonstrated activity in patients with AD. Results of short-term, open-label studies show interferon gamma to be a welltolerated and potentially effective treatment for patients with AD 5 and the optimal dose to be 50 µg/m 2 . 6 In a 12-week, double-blind, placebo-controlled study, interferon gamma was superior to placebo in the improvement of overall severity, erythema, and excoriations and erosion.…”

mentioning

confidence: 99%

Long-term Effectiveness and Safety of Recombinant Human Interferon Gamma Therapy for Atopic Dermatitis Despite Unchanged Serum IgE Levels

Stevens¹,

Hanifin²,

Hamilton³

et al. 1998

Arch Dermatol

125

View full text Add to dashboard Cite

mentioning

confidence: 99%

Long-term Effectiveness and Safety of Recombinant Human Interferon Gamma Therapy for Atopic Dermatitis Despite Unchanged Serum IgE Levels

Stevens¹,

Hanifin²,

Hamilton³

et al. 1998

Arch Dermatol

125

View full text Add to dashboard Cite

“…This phenomenon is also reflected in reports of some clinical trials of IFN-γ treatment in atopic patients [43, 44]. This situation could be related to the fluctuating levels of IgE in response to several uncontrolled factors that influence IgE synthesis.…”

Section: Discussionmentioning

confidence: 79%

Immunoglobulin E-Dependent Regulation of the CCR3 Chemokine Receptor by Interferon-Gamma in Atopic Asthmatics

García-Vega¹,

Rodríguez-Perez²,

Bermúdez-Badell³

et al. 2008

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: The chemokine receptor CCR3 mediates the migration of cells that play an important role in the pathogenesis of asthma to inflammatory foci. Interferon (IFN)-γ is known to downregulate the expression of some chemokine receptors. Therefore, we decided to analyze the regulation of CCR3 by IFN-γ in asthmatics and to characterize the dependence of this process on immunoglobulin E (IgE) levels. Methods: Atopic asthmatics were treated with IFN-γ or placebo, and the IgE concentration in the blood was measured using an ultra-micro-ELISA for total IgE. Mononuclear cells from patients and controls were isolated by Ficoll-Hypaque gradient and incubated in the absence or presence of IFN-γ for different periods of time. After incubation, the cells were washed and lysed for RT-PCR analysis, which was performed using a Perkin-Elmer kit. Results: IFN-γ treatment apparently improved the evaluated clinical variables; however, the differences were not significant compared to the placebo group. We found that IFN-γ downregulated CCR3 mRNA expression ex vivo and in vivo in those patients with IgE levels higher than 500 IU/ml, whereas IFN-γ upregulated CCR3 mRNA expression in patients with IgE levels lower than 500 IU/ml. Correspondence between ex vivo and in vivo results was observed using this approach. There was found to be a direct correlation between total serum IgE and CCR3 mRNA expression. Conclusions: In those asthmatic patients with high levels of IgE, who are thus susceptible to downregulation of CCR3 by IFN-γ, a significant therapeutic effect with systemic IFN-γ might be expected.

show abstract

“…In view of the imbalance between decreased IFN-y and high interleukin (1L)-4 production in patients with atopic eczema, recent research has focused on the effect of IFN-y in the treatment of severe atopic eczema. Subcutaneous injection of 3 x lo6; i.e., IFN-y three times a week, resulted in marked clinical improvement of the skin condition (102). In a randomized, placebocontrolled, double-blind study, IFN-y given by daily subcutaneous injection over a 12-week period was safe, well accepted, and effective in reducing inflammation and clinical symptoms (103), although the overall response was not as dramatic as in the study mentioned before.…”

Section: Therupeutic Possibilities In Patients Not Responding To Convmentioning

confidence: 94%

The therapeutic concept of “patient management” in atopic eczema

Ring

Brockow

Abeck

1996

Allergy

View full text Add to dashboard Cite

Systemic interferon gamma treatment in severe atopic dermatitis

Cited by 91 publications

References 13 publications

Long-term Effectiveness and Safety of Recombinant Human Interferon Gamma Therapy for Atopic Dermatitis Despite Unchanged Serum IgE Levels

Long-term Effectiveness and Safety of Recombinant Human Interferon Gamma Therapy for Atopic Dermatitis Despite Unchanged Serum IgE Levels

Immunoglobulin E-Dependent Regulation of the CCR3 Chemokine Receptor by Interferon-Gamma in Atopic Asthmatics

The therapeutic concept of “patient management” in atopic eczema

Contact Info

Product

Resources

About